{"entity":{"id":"cart84","kind":"drug","name":"CART84","aka":[],"tldr":"CART84 is an experimental CAR-T cell therapy from Gyala Therapeutics in phase 2 trials for acute myeloid leukaemia, aimed at CD3.","summary":"CART84 is a CAR-T cell therapy developed by Gyala Therapeutics. Its target is CD3 (the sponsor names CD84). The sponsor states: Autologous T cells transduced with a lentiviral vector expressing an anti-CD84 chimeric antigen receptor, to recognise and kill CD84-expressing leukaemia cells. ClinicalTrials.gov describes the intervention as: GYA01 (CART84): autologous cell-based product containing CD3+ T cells transduced with a lentiviral vector expressing an anti-CD84 chimeric antigen receptor (CAR). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in acute myeloid leukaemia. The largest, NCT07471789, plans to enrol 33 participants with primary completion expected 2029-05-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of CART84","url":"https://clinicaltrials.gov/search?intr=CART84"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":["cd3"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07471789"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"CAR-T cell therapy","mechanism":"Autologous T cells transduced with a lentiviral vector expressing an anti-CD84 chimeric antigen receptor, to recognise and kill CD84-expressing leukaemia cells.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/cart84/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"target":[{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"}],"trial":[{"id":"nct07471789","kind":"trial","name":"Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).","route":"/trials/nct07471789/"}]}}